key: cord-0768811-u333cr6v
authors: nan
title: PD-1单抗导致免疫检查点抑制剂相关肺炎1例——吡非尼酮治疗的安全性和有效性
date: 2021-07-20
journal: Zhongguo Fei Ai Za Zhi
DOI: 10.3779/j.issn.1009-3419.2021.103.08
sha: e1d398e20a05964ae5ec66732d723d97877bba2f
doc_id: 768811
cord_uid: u333cr6v

BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitor associated pneumonia (CIP) is a serious side effect of immune checkpoint inhibitors. There is a consensus on the treatment of acute phase of CIP, but the treatment of pulmonary interstitial fibrosis after the acute phase is still a clinical problem to be solved. METHODS: The diagnosis and treatment of a non-small cell lung cancer (NSCLC) patient with immune checkpoint inhibitor associated pneumonia in the Stereotactic Radiotherapy Department of Qingdao Central Hospital were retrospectively analyzed, and literatures were reviewed. RESULTS: A 70-year-old male patient was diagnosed with Poorly differentiated squamous cell carcinoma of left lung with mediastinal lymph node metastasis T3N3M0 stage Ⅲc, EGFR/ALK/ROS1/RAF negative, PD-L1 (22c3) immunohistochemistry negative. After the progression of first-line chemotherapy, the patient was diagnosed as immune checkpoint inhibitor associated pneumonia grade 3 during second-line monotherapy with Nivolumab. After initial high-dose glucocorticoid pulse therapy, the lung computed tomography (CT) imaging and clinical symptoms of the patients were partially relieved, and then pirfenidone (300 mg tid) was given orally for more than 11 months. During the treatment of pirfenidone, the CT imaging and clinical symptoms of the patients were significantly improved, and there were no other adverse reactions except grade 1 nausea. During this period, chemotherapy and Anlotinib was given concurrently with pirfenidone and showed good safety profile. CONCLUSION: This case report is the first report of pirfenidone in the treatment of CIP, which provides a new idea for the clinical practice and research of CIP treatment.

www.lungca.org www.lungca.org 患者的irAE在及时治疗后均可得到明显缓解，总体安全 性可控 [11] [12] [13] 。再挑战距离首次ICI治疗时间长的再次发生 irAE的可能性较低 [13] 。在ICIs再挑战的2个非小细胞肺癌 小样本研究中，再挑战的客观缓解率为5.9%-13%，疾病 控制率可达到58.8% [12, 14] 。有两个小样本研究对既往ICI 疗效与再挑战疗效的相关性进行了分析，发现既往ICI 疗效SD的患者疾病控制率可达到77.8%，甚至优于既往 ICI疗效为PR的患者 [12, 14] www.lungca.org

Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study

Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer

Immune checkpoints as promising targets for the treatment of idiopathic pulmonary fibrosis?

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma

Safety and efficacy of retreating with immunotherapy after immune-related adverse events in patients with NSCLC

Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer

Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case Series and Literature Review

Fatal adverse events associated with programmed cell death ligand 1 inhibitors: a systematic review and metaanalysis

A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1 Antibody-Safety and Effectiveness of Pirfenidone